CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

The first public capital markets transaction of CHEPLAPHARM Arzneimittel GmbH will be closed in the near future, following a diligent and intensive preparation. Prior to that, the initial rating process with the leading rating agencies S&P and Moody’s were successfully completed.

Based on individual discussions with the rating agencies, the management board had to answer numerous questions in detail. Furthermore, an extensive illustration of the business model and the business strategy was presented. With the now published rating results of B/B1 (both with stable outlook) CHEPLAPHARM’s management is feeling very content.

CFO Jens Rothstein commenting on the outcome: "The healthy debt structure is the main pillar of our business strategy, building the basis for the continuous growth of turnover and profit. So we are kind of pioneers in Mecklenburg-Western Pomerania among the family-owned companies and will continue to further develop our Capital Markets strategy."

Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)cheplapharm.com


Investor Relations topics

Back to top expand_less